Press release
Future Outlook: Herceptin Biosimilars Market to Hit USD 21,271.43 Million by 2034, Growing at 22.9%
Herceptin Biosimilars Market
The Herceptin Biosimilars market was valued at USD 2,711.22 million in 2024. It is expected to reach USD 21,271.43 million by 2034, exhibiting a compound annual growth rate (CAGR) of 22.9% from 2025 to 2034.
Market Overview
Herceptin, also known as trastuzumab, is a biosimilar injectable biologic medicine. Biologics are complex drugs derived from living organisms or organic sources such as bacteria, proteins, and sugars. Herceptin is typically administered as an intravenous (IV) infusion every 1 to 3 weeks and may be given alone or in combination with chemotherapy.
Once administered, Herceptin works by targeting cancer in a specific way. It is a targeted therapy classified as a human epidermal growth factor receptor 2 (HER2) blocker. HER2 is a protein that promotes the rapid growth of cancer cells. By binding to and blocking HER2, Herceptin helps stop cancer cells from growing.
Cancers that have an overexpression of HER2 receptors are referred to as HER2-positive. Due to its mechanism of action, Herceptin is widely used in the treatment of HER2-positive breast cancer and HER2-positive stomach (gastric) cancer.
Request For a Sample with An Exclusive Look at the Latest Trends and Upcoming Advancements:
https://www.polarismarketresearch.com/industry-analysis/herceptin-biosimilars-market/request-for-sample
Key Growth Drivers
• Growing Cases of Breast and Gastric Cancers: The growing worldwide cases of HER2-positive breast and gastric cancers are a notable market driver for Herceptin biosimilars. As per the research published by the National Institutes of Health (NIH) website in 2023, a study titled "Global Burden of Breast Cancer" underscored a continuous surge in breast cancer therapies globally, with a sizeable percentage being HER2 positive. This growing patient population is having a favourable impact on the herceptin biosimilars market demand.
• Cost Containment Pressures in Healthcare Systems: The growing costs of healthcare worldwide are coercing notable pressure on healthcare systems and payers, making budget management an important market driver for the adoption of biosimilars, including Herceptin biosimilars. A publication on the World Health Organization (WHO) website in 2021, discussing "Sustainable access to medicines: addressing the challenges of high-priced medicines," highlighted the escalated concerns over fiscal sustainability of healthcare and cost-effectiveness of biosimilars.
Need More Information? Inquire more about this report before purchase:
https://www.polarismarketresearch.com/industry-analysis/herceptin-biosimilars-market/inquire-before-buying
Competitive Landscape
The competitive landscape of the market reflects a dynamic environment, characterized by the expanding presence of biosimilars that replicate trastuzumab, commonly used in the treatment of HER2-positive breast cancer. Some of the key players currently operating in the market include:
• Amgen Inc.
• Biocon Biologics Limited
• Celltrion Healthcare Co., Ltd.
• Innovent Biologics, Inc.
• Mylan Pharmaceuticals Inc.
• Novartis AG
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Shanghai Henlius Biotech, Inc.
• Teva Pharmaceutical Industries Ltd.
Market Segmentation
The herceptin biosimilars market segmentation is done on the basis of application, dosage, end users, distribution channel, and region.
By application analysis, the breast cancer segment currently holds the largest market share owing to the growing existence of HER2-positive breast cancer, which is a notable sign for trastuzumab cure.
By dosage analysis, the 150mg/single-dose vial segment presently accounts for a larger market share owing to established prescribing practices and the flexibility offered by single-dose vials.
Browse Full Report:
https://www.polarismarketresearch.com/industry-analysis/herceptin-biosimilars-market
Regional Analysis
Regional analysis provides an examination of the key variables, including social, physical, and economic, in a regional context. It helps companies understand the needs and wants of their customers in target markets. Thus, stakeholders can make informed decisions about their products or service offerings. Also, regional analysis assists businesses in identifying regions with high growth potential and where they should focus their efforts. Furthermore, it can help stakeholders understand local conditions to analyze policy related to global change.
The key regions and sub-regions of the Herceptin Biosimilars Market covered in the research report are:
• North America (U.S., Canada)
• Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
• Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
• Latin America (Brazil, Mexico, Argentina)
• Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)
Top Trending Reports of Polaris Market Research:
Biotechnology Market
https://www.polarismarketresearch.com/industry-analysis/biotechnology-market
E-Pharmacy Market
https://www.polarismarketresearch.com/industry-analysis/e-pharma-market
Cell Culture Market
https://www.polarismarketresearch.com/industry-analysis/cell-culture-market
Virus Filtration Market
https://www.polarismarketresearch.com/industry-analysis/virus-filtration-market
Optimizing Clinical Trial Designs with AI in Drug Discovery Market
https://www.polarismarketresearch.com/blog/optimizing-clinical-trial-designs-with-ai-in-drug-discovery-market
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Future Outlook: Herceptin Biosimilars Market to Hit USD 21,271.43 Million by 2034, Growing at 22.9% here
News-ID: 4034887 • Views: …
More Releases from Polaris Market Research & Consulting
Vibration Damping Material Market is Expanding at a 4.4% Predicted to Reach US$ …
The vibration damping material market is poised to register robust growth, according to the latest research report by Polaris Market Research. The market was valued at USD 10.54 billion in 2024 and is projected to grow to USD 16.20 billion by 2034. It is anticipated to register a CAGR of 4.4% during 2025-2034.
Market Introduction:
Vibration damping materials are specialized substances used to reduce or absorb vibrations, noise, and mechanical energy in…
Smart Water Management Market to Reach USD 66.46 Billion by 2034, Growing at a C …
Polaris Market Research examines the smart water management market to register a robust CAGR of 13.3% during 2025-2034. The market was valued at USD 19.11 billion in 2024 and is projected to grow to USD 66.46 billion by 2034.
Market Introduction:
Smart water management refers to the use of advanced technologies and data-driven solutions to efficiently monitor, control, and optimize the distribution, usage, and quality of water resources. It integrates Internet…
Polyurea Coatings Market Expected to Hit USD 3,876.26 Million by 2034, Expanding …
The market for polyurea coatings is poised to register a robust CAGR of 10.4% during 2025-2034. The market was valued at USD 1,447.12 million in 2024 and is projected to grow to USD 3,876.26 million by 2034.
Market Introduction
Polyurea coatings are advanced protective coatings known for their exceptional durability, flexibility, and rapid curing time. These coatings are created through a chemical reaction between an isocyanate component and a resin…
Security Operations Center (SOC) Market Projected to Reach USD 91.88 Billion by …
Polaris Market Research projects the global security operations center (SOC) market to reach a valuation of nearly USD 91.88 billion by the end of 2034 from USD 42.85 billion in 2024, with a CAGR of 7.9% during the forecast period from 2025 to 2034.
Market Explanation
A security operations center (SOC) enhances a firm's threat detection, response, and prohibition potential by integrating and coordinating all cybersecurity technologies and operations. It consists of…
More Releases for Herceptin
Herceptin Biosimilar Market | Industry Trends and Forecast 2022-2030
Acumen Research and Consulting has announced the addition of the "Herceptin Biosimilar Market" report to their offering.
The Herceptin Biosimilar Market Report 2030 is an in depth study analyzing the current state of the Herceptin Biosimilar Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Herceptin Biosimilar Market provides analysis of global market covering the industry trends, recent…
Herceptin Biosimilar Market 2021 Growth, COVID Impact, Trends Analysis Report 20 …
Herceptin is an anticancer drug used to treat breast cancer. It is a monoclonal antibody and is used with chemotherapy drugs. Also called targeted therapy. Trastuzumab is one of the brand name Herceptins, given by slow injection into a vein.
Herceptin Biosimilar Market is thoroughly, accurate and comprehensively assessed in a report focusing on market dynamics, market competition, regional growth, segment analysis, and key growth strategies. Report buyers will have access…
Herceptin Biosimilar Market to Exhibit Skyrocketing Expansion During 2020-2027
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry…
Herceptin Biosimilar Market to Discern Steadfast Expansion During 2029
Global Herceptin Biosimilar Market: Overview
Growing number of people living with gastric cancers and metastatic (spread) breast cancer is expected to drive demand opportunities for enterprises working in the global herceptin biosimilar market. Herceptin refers to a monoclonal antibody mainly utilized in the treatment of critical cancers like gastric cancers and metastatic (spread) breast cancer.
An upcoming research report on the global herceptin biosimilar market provides a complete analysis of this market.…
United States Herceptin Biosimilar Market 2017
In this report, the United States Herceptin Biosimilar Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Herceptin Biosimilar in…
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014.
Trastuzumab or…
